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http://www.biomedcentral.com/1471-2369/14/270RESEARCH ARTICLE Open AccessUrinary Neutrophil Gelatinase-Associated
Lipocalin predicts the severity of contrast-induced
acute kidney injury in chronic kidney disease
patients undergoing elective coronary procedures
Adis Tasanarong1*, Pisit Hutayanon2 and Dilok Piyayotai2Abstract
Background: Contrast-induced acute kidney injury (CI-AKI) particularly in high risk patients with chronic kidney
disease (CKD), increases morbidity and mortality. Neutrophil gelatinase-associated lipocalin (NGAL) is a protein
excreted by the kidney during AKI. There are no urine (u) NGAL data as an early CI-AKI marker in CKD patients
undergoing coronary procedures.
Methods: This prospective study enrolled 130 patients with estimated glomerular filtration rate (eGFR) < 60 ml/min/
1.73 m2 undergoing elective coronary procedures. Serial urine samples, obtained at baseline and 3, 6, 12, 18, and 24 h
post contrast administration were analyzed by NGAL ELISA kit. AKI was defined as an increase in serum creatinine (SCr)
of≥ 0.3 mg/dl or≥ 1.5 times baseline SCr within 48 h per 2012 KDIGO guidelines. Receiver operator characteristic curve
analyses identified optimal uNGAL and delta of uNGAL values for diagnosing CI-AKI.
Results: The uNGAL was significantly and inverse correlated with eGFR (R = 0.25, P < 0.005). CI-AKI developed in 16/130
(12.31%) patients: 13 and 3 in CI-AKI stages I and II, respectively. uNGAL and delta of uNGAL were significantly higher
in the CI-AKI group when compared with the No CI-AKI group (P < 0.05). The best uNGAL cut-off for optimal
sensitivity 94%, specificity 78%, and area under the curve 0.84 for predicting CI-AKI was 117 ng/mL at 6 h, respectively.
Corresponding values for predicting CI-AKI stage II were 100%, 87% and 0.9 when using an uNGAL of 264 ng/mL
at 6 h.
Conclusions: Monitoring of uNGAL levels not only provide the early detecting CI-AKI but also predict the severity of
CI-AKI in CKD patients undergoing elective coronary procedures.
Keywords: Neutrophil Gelatinase-Associated Lipocalin (NGAL), Contrast Induced Acute Kidney Injury (CI-AKI), Chronic
Kidney injury (CKD), Coronary proceduresBackground
Contrast-induced acute kidney injury (CI-AKI) is one of
the most common complications in patients who receive
intravenous contrast media [1-4]. The incidence of CI-
AKI is low 1–2% in patients with normal renal function
even with underlying diabetes mellitus [1] but increases
up to 25% in patients with certified risk factors, for* Correspondence: adis_tasanarong@hotmail.com
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distribution, and reproduction in any mediuminstance the combination of chronic kidney disease
(CKD) and diabetes, congestive heart failure, advanced
age, and concurrent use of nephrotoxic drugs [4] with
raising the morbidity and mortality [5]. CI-AKI requiring
dialysis occurs in 3-4% of patients with underlying CKD
undergoing coronary procedures [6,7] and CI-AKI in
CKD patients contributes to extended hospitalizations
and increases long-term morbidity and mortality [8].
CI-AKI is defined as an acute deterioration in renal func-
tion after intravenous administration of contrast media by
an absolute increase in serum creatinine (SCr) ≥ 0.5 mg/dL
or ≥ 25% relative increase from baseline SCr within 48 hoursntral Ltd. This is an open access article distributed under the terms of the
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causes. In general, impairment of renal function in CI-AKI
occurs within 3 days after intravenous administration of
contrast media, while the peak of SCr is observed at 3–
5 days and returns to the baseline value within 1–3 weeks
[9,10]. However, SCr is an unreliable biomarker during AKI
in kidney function [11,12] because many factors can affect
SCr concentration, including creatinine generation by
muscle catabolism, diet, age, hydration status and renal
tubular secretion of creatinine. In addition, during an
acute decrease in glomerular filtration rate, SCr does not
accurately represent kidney function in AKI until steady
state has been reached, which requires several days
[13,14]. Consequently, a changing of SCr within 48 hours
after contrast media injection might result in a delay for
diagnosis CI-AKI. The earlier detection of CI-AKI with
another biomarker/s could be diagnostically and thera-
peutically beneficial.
The Neutrophil Gelatinase-Associated Lipocalin (NGAL)
is a protein covalently bound to gelatinase in neutrophils
which is usually expressed at very low concentrations in
several human tissues, including kidney, lung, stomach,
and colon [15]. During AKI, NGAL expression is mark-
edly induced systemically and in injured distal nephron
epithelium. Urine (u) NGAL concentrations are increased
because of impaired reabsorption of NGAL by the dam-
aged proximal tubules and direct excretion by the dam-
aged distal tubules [16]. NGAL was detected easily in the
blood and urine soon after AKI in experimental and clin-
ical studies [17,18]. Therefore, NGAL has proved an early,
sensitive, non-invasive biomarker for AKI in different
clinical settings such as in cardiac surgery [19,20], critical
care [21,22], and kidney transplantation [23,24].
Previous studies of uNGAL in CI-AKI have been
conducted in adult and pediatric patients with normal
renal function [25-28]. Given the lack of data in CKD
patients undergoing coronary procedures, the present
study was conducted to evaluate uNGAL as an early
biomarker for the diagnosis and severity of CI-AKI.
Methods
Patient population
The prospective cohort study was conducted in patients
who underwent clinically-driven, elective coronary angi-
ography and/or intervention at Thammasat Chalerm
Prakiat Hospital during the period from January 2010 to
December 2011. Approval was obtained from the Ethics
Committee of the Faculty of Medicine, Thammasat
University. All patients provided written, informed con-
sent to participate in the study. Patients aged ≥ 18 years
with baseline estimation of glomerular filtration rate
(eGFR) < 60 mL/min, as measured in their most recent
sample and at least two measurements for ≥ three
months prior to the beginning of the protocol, wereincluded in the study. Stages of CKD were classified by
the National Kidney Foundation practice guidelines [29].
However, patients who younger than 18 years, with
pre-existing AKI, CKD stage 5 or unstable renal function
(as evidenced by a change in SCr of ≥ 0.5 mg/dL, or ≥ 25%,
within 14 days prior to the study) were excluded from
further participation. Subjects were also excluded if they
had a known allergy to any of the contrast agents, or were
receiving mechanical ventilation, or suffered from con-
gestive heart failure, cardiogenic shock or emergent
angiography. Moreover, those receiving NAC, mannitol,
diuretics, theophylline, dopamine, and ascorbic acid or
contrast agents within 14 days before study commence-
ment were not included.
All subjects were maintained in a euvolemic state with
intravenous isotonic (0.9%) saline at rate 1 mL/kg per
hour for 12 hours before and 12 hours after elective
coronary procedures. Variation in the hydration rate was
allowed for adjustments according to the clinical heart
failure of individual patient. Hospital procedures man-
dated accurate hourly recording of all in-hospital volume
inputs for patients undergoing elective coronary inter-
ventions. All patients were encouraged to drink if they
were thirsty. Coronary intervention was performed using
a standard protocol, via either the radial or femoral
approach by the attending interventional cardiologist.
All procedures were performed using low-osmolar, non-
ionic contrast media agent (Iopromide, Schering AG,
Germany) in doses adjusted for body weight and deter-
mined by the number and location of cardiovascular
angiograms.
Blood and urine sample collections and storage
Venous blood samples were collected for the measure-
ment of complete blood count, and SCr baseline levels
12–24 hrs prior to intervention and again 48 hrs after
the procedure. eGFR was calculated by using the reex-
pressed 4-variable Modification of Diet in Renal Disease
(MDRD) equation, where eGFR = 175 × plasma creatin-
ine−1.154 × age−0.203 (× 0.742 if female; × 1.212 if African
American) [30]. Serial urine samples were collected at
baseline (prior to coronary procedures), and at 3, 6, 12,
18 and 24 h post coronary procedures. Samples were
centrifuged at 2,000 g for 5 min and the supernatants
stored at −70°C until assayed.
uNGAL concentrations were measured using a com-
mercially available ELISA kit (Antibody Shop, Gentofte,
Denmark), following the manufacturer’s instructions. All
urine specimens were diluted to achieve concentration
for optimal density according to the ELISA kit instruction
before performing an ELISA assay to fit the concentrations
of respective NGAL protein in the linear range of the
standard curve. The inter-assay and intra-assay coefficients
of variation for NGAL were < 5%. The measurements were
Figure 1 Diagram showing the flow of patients through each
step of trial.
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were expressed in units of nanograms per milliliter.
Newer criteria of AKI from KDIGO guideline 2012
were applied for the diagnosis of CI-AKI. AKI was defi-
ned as an increase in SCr of ≥ 0.3 mg/dl or ≥ 1.5 times
baseline creatinine within 48 hr, and the patients were
classified into three stages according to the SCr criteria.
Stage I defined as a SCr increase of ≥ 0.3 mg/dl or ≥ 1.5
to 1.9 times baseline; stage II as a SCr increase to ≥ 2.0
to 2.9 times and stage III of more than 3 times baseline.
Urine criteria of AKI were not utilized in this study
because of potential changes in urinary volume induced
by some medical therapy.
The risk score for predicting CI-AKI development was
calculated according to Mehran et al. [31]. Risk score
assessment was evaluated by definition of clinical and
cut-off point of laboratory investigation. Specific clinical
and laboratory data were obtained from the hospital
charts that were reviewed by research investigators.
Statistical analysis
Values are presented as mean ± standard error of the
mean (SE). A two-sample t-test or the non-parametric
Mann–Whitney U test was used to compare continuous
variables. Categorical variables were compared using the
chi-square test or Fisher’s exact test, as appropriate. The
associations between two continuous variables were
assessed by Pearson’s correlation coefficient; all non-
normally distributed values were log-transformed as
required. To measure the sensitivity and specificity of
uNGAL for the diagnosis of CI-AKI and its severity,
receiver-operating characteristic (ROC) curves were gen-
erated and the area under the curve (AUC) calculated. We
defined the cut-off as closest point to sensitivity = specifi-
city = 1.0 on ROC curve. An AUC-ROC value of 0.90 to
1.0 indicated excellent, 0.80 to 0.89 good, 0.70 to 0.79 fair,
0.60 to 0.69 poor, and 0.50 to 0.59 indicated no useful
value. The AUC ROCs were compared according to the
method of Hanley and McNeil [32]. Two tailed p < 0.05
was considered statistically significant. The SPSS version
16 for Windows software was used for analyses.
Results
A total of 1,393 patients referred for coronary angiography
and/or intervention were screened between January 2010
and December 2011 (Figure 1). Of these patients, 301
patients met the inclusion criteria based on a baseline
eGFR < 60 mL/min. 171 patients were excluded from the
study because 18 patients declined to participate, two
patients suffered from congestive heart failure, three
patients developed AKI and 148 patients were enrolled in
other study. Finally, 130 CKD patients were included in
the present study: CKD stage III and CKD stage IV
numbered 100 and 30 patients, respectively.After coronary procedures, 16/130 (12.31%) patients
developed CI-AKI; 13 patients for CI-AKI stage I, and 3
patients for CI-AKI stage II. CI-AKI developed in 10/100
(10%) in patients with CKD stage III; 9 patients for
CI-AKI stage I, and 1 patient for CI-AKI stage II. While,
CI-AKI developed in 6/30 (20%) in patients with CKD
stage IV; 4 patients for CI-AKI stage I, and 2 patients for
CI-AKI stage II. Based on the primary outcome, we
classified subjects into those with and without CI-AKI
(No CI-AKI).
The baseline clinical characteristics of patients, strati-
fied by the presence/absence of baseline CI-AKI are
shown in Table 1. Comparing these two groups, there
were no statistically significant differences in age, sex,
blood pressure, heart rate, body mass index, concomitant
medication, and co-morbidity, including hypertension,
diabetes mellitus, hypercholesterolemia, left ventricular
ejection fraction, myocardial infarction, Canadian Cardio-
vascular Society classification, New York Heart Association
classification, angiography/percutaneous intervention and
number of vessel disease. Similarly, no statistically signifi-
cant differences between the groups, especially contrast
volume, intravenous volume and risk score.
The baseline, follow-up and absolute changes (from
baseline) for SCr, eGFR, uNGAL and delta of uNGAL in
each group of all patients, CKD stage III and CKD stage
Table 1 /Baseline demographics in patients undergoing elective coronary procedures
Characteristic No CI-AKI CI-AKI CI-AKI (S1) CI-AKI (S2) P value
Number of subject 114 16 13 3
CKD stage III: CKD stage IV 90:24 10:6 9:4 1:2
Age (yr) 70 ± 10 72 ± 7 73 ± 5 70 ± 9 0.67
Men: women 88:26 12:4 10:3 2:1 0.17
SBP (mmHg) 129 ± 17 125 ± 13 125 ± 14 124 ± 14 0.65
DBP(mmHg) 71 ± 10 69 ± 12 70 ± 12 67 ± 8 0.74
Heart rate 75 ± 10 74 ± 12 76 ± 11 72 ± 8 0.48
Height (cm) 162 ± 9 161 ± 9 160 ± 7 162 ± 8 0.85
Weight (kg) 60 ± 13 56 ± 7 58 ± 5 54 ± 8 0.16
Body mass index (kg/m2) 24 ± 4 23 ± 3 23 ± 3 21 ± 4 0.14
Diabetes mellitus (%) 42 44 46 33 0.25
Hypertension (%) 80 75 77 67 0.19
Hypercholesterolemia (%) 50 44 38 67 0.16
Myocardial infarction (%) 18 25 23 33 0.37
LVEF < 40% (%) 20 19 15 33 0.59
CCS > II (%) 96 94 92 100 0.49
NYHA > II (%) 44 44 38 67 0.6
Angiogram/PCI (%) 66 75 85 67 0.58
Number of vessel disease > 1 (%) 61 63 50 67 0.62
ACEI (%) 30 31 31 33 0.42
ATRA (%) 40 31 31 33 0.48
Beta blocker (%) 54 44 38 67 0.56
CCB (%) 28 31 31 33 0.26
Diuretic (%) 26 31 31 33 0.64
Aspirin (%) 72 63 62 67 0.51
Statin (%) 48 44 38 67 0.17
Nitrate (%) 38 38 31 67 0.14
Contrast volume (ml) 126 ± 65 129 ± 90 126 ± 80 124 ± 92 0.43
IV volume (ml) 1483 ± 453 1591 ± 260 1598 ± 246 1562 ± 128 0.48
Total risk score 8 ± 3 8 ± 3 8 ± 3 9 ± 1 0.24
CI-AKI indicates contrast induced acute kidney injury, CI-AKI (S1) indicates CI-AKI stage I, CI-AKI (S2) indicates CI-AKI stage II, SBP indicates systolic blood pressure,
DBP indicates diastolic blood pressure, LVEF indicates left ventricular ejection fraction, CCS indicates Canadian Cardiovascular Society, NYHA indicates New York
Heart Association, PCI indicates percutaneous intervention, CCB indicates calcium channel blocker.
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stage IV patients (but not CKD stage III patients), the
CI-AKI group had a significantly higher SCr but lower
eGFR at baseline (P < 0.05) (Table 2A, 2B and 2C). The
CI-AKI group had a significant increase in SCr and
decrease in eGFR at 48 h post coronary procedures for
all patients, CKD stage III and IV patients (P < 0.05). On
average at 48 h, patients in the CI-AKI group had a sta-
tistically significant increase in SCr of 55% (all patients),
73% (CKD stage III) and 42% (CKD stage IV), while
corresponding decrease in eGFR were 33.33%, 50% and
35% (P < 0.05) respectively. The mean SCr and eGFR didnot change significantly in the No CI-AKI group
(Table 2).
In all patients and patients with CKD stage IV, the
mean uNGAL levels at baseline were significantly higher
in the CI-AKI when compared to No CI-AKI group
(P < 0.05) (Table 2A and 2C) but without a statisti-
cally significant difference in CKD stage III patients
(Table 2B). The CI-AKI group had a significant increase in
uNGAL and delta of uNGAL at all time points post
coronary procedures when compared to No CI-AKI group
(P < 0.05). Comparing CI-AKI stages I and II, there were
not significant differences in uNGAL levels at any time
Table 2 Baseline, follow-up and absolute changes (from
baseline) for serum creatinine, eGFR, urine NGAL and
delta of urine NGAL in each group of all patients (2A),
CKD stage III (2B) and CKD stage IV (2C)
2A
Characteristic All patients
No CI-AKI CI-AKI CI-AKI (S1) CI-AKI (S2)
( N = 114) (N = 16) (N = 13) (N = 3)
Serum creatinine
(mg/dL)
Baseline 1.4 ± 0.4 2.0 ± 0.6a 2.0 ± 0.6a 1.9 ± 0.3a
Follow-up
(48 hr after)
1.3 ± 0.4 3.1 ± 1.1a 2.7 ± 1.1a 4.5 ± 0.4a,b
Absolute change 0.0 ± 0.2 1.1 ± 0.9a 0.7 ± 0.9a 2.7 ± 0.6a,b
eGFR (ml/min)
Baseline 44 ± 16 27 ± 7a 27 ± 8a 28 ± 3a
Follow-up
(48 hr after)
45 ± 17 18 ± 6a 20 ± 6a 11 ± 2a,b
Absolute change 1 ± 5 −9 ± 5a −7 ± 3a −17 ± 2a,b
Urine NGAL (ng/ml)
Baseline 68 ± 99 144 ± 111a 154 ± 143a 113 ± 45a
3 h 79 ± 102 211 ± 120a 213 ± 159a 202 ± 60a
6 h 93 ± 129 267 ± 153a 255 ± 191a 316 ± 86a
12 h 115 ± 166 277 ± 169a 256 ± 181a 352 ± 133a
18 h 132 ± 175 298 ± 171a 315 ± 187a 272 ± 80a
24 h 122 ± 165 294 ± 162a 314 ± 173a 265 ± 52a
Delta urine NGAL
(ng/ml)
0-3 h 10 ± 92 66 ± 78a 59 ± 81a 99 ± 61a
0-6 h 24 ± 110 122 ± 87a 101 ± 72a 213 ± 101a,b
0-12 h 42 ± 158 132 ± 91a 112 ± 76a 242 ± 104a,b
0-18 h 59 ± 142 135 ± 136a 137 ± 147a 159 ± 95a
0-24 h 49 ± 149 149 ± 136a 160 ± 136a 151 ± 80a
2B
Characteristic CKD stage III
No CI-AKI) CI-AKI CI-AKI (S1) CI-AKI (S2)
(N = 90 (N = 10) (N = 9) (N = 1)
Serum creatinine
(mg/dL)
Baseline 1.3 ± 0.3 1.5 ± 0.5 1.5 ± 0.7 1.6
Follow-up
(48 hr after)
1.2 ± 0.3 2.7 ± 1.0a 2.5 ± 0.9a 4.6a,b
Absolute change −0.1 ± 0.2 1.1 ± 0.8a 0.9 ± 0.3a 3.0a,b
eGFR (ml/min)
Baseline 46 ± 14 44 ± 9 43 ± 9 43
Follow-up
(48 hr after)
48 ± 11 22 ± 8a 24 ± 8a 14a,b
Absolute change 1 ± 6 −22 ± 9a −18 ± 6a −29a,b
Urine NGAL (ng/ml)
Baseline 61 ± 81 72 ± 45 75 ± 42 98
Table 2 Baseline, follow-up and absolute changes (from
baseline) for serum creatinine, eGFR, urine NGAL and
delta of urine NGAL in each group of all patients (2A),
CKD stage III (2B) and CKD stage IV (2C) (Continued)
3 h 75 ± 83 145 ± 73a 136 ± 72a 220a
6 h 84 ± 119 171 ± 75a 160 ± 70a 264a
12 h 113 ± 162 181 ± 86a 178 ± 78a 208a
18 h 121 ± 161 205 ± 210a 203 ± 79a 226a
24 h 114 ± 163 210 ± 87a 210 ± 93a 204a
Delta of urine
NGAL (ng/ml)
0-3 h 13 ± 80 63 ± 42a 62 ± 64a 122a
0-6 h 22 ± 104 89 ± 87a 85 ± 86a 166a
0-12 h 49 ± 136 99 ± 91a 103 ± 63a 110a
0-18 h 54 ± 131 124 ± 136a 128 ± 55a 128a
0-24 h 46 ± 143 128 ± 136a 135 ± 82a 106a
2C
Characteristic CKD stage IV
No CI-AKI CI-AKI CI-AKI (S1) CI-AKI (S2)
(N = 24) (N = 6) (N = 4) (N = 2)
Serum creatinine
(mg/dL)
Baseline 1.7 ± 0.5 2.4 ± 0.6a 2.3 ± 0.6a 2.5 ± 0.3a
Follow-up
(48 hr after)
1.6 ± 0.6 3.3 ± 1.3a 2.9 ± 0.9a 4.5 ± 0.6a,b
Absolute change −0.1 ± 0.3 1.0 ± 1.2a 0.6 ± 0.4a 2.1 ± 0.8a,b
eGFR (ml/min)
Baseline 27 ± 3 20 ± 4a 21 ± 5a 19 ± 3a
Follow-up
(48 hr after)
27 ± 4 14 ± 6a 15 ± 8a 9 ± 4a,b
Absolute change 0 ± 3 −7 ± 6a −6 ± 4a −10 ± 4a,b
Urine NGAL (ng/ml)
Baseline 102 ± 98 217 ± 180a 216 ± 231a 218 ± 145a
3 h 116 ± 157 314 ± 251a 340 ± 318a 261 ± 153a
6 h 134 ± 162 404 ± 227a 444 ± 280a 324 ± 124a
12 h 132 ± 191 409 ± 192a 415 ± 239a 396 ± 107a
18 h 193 ± 230 394 ± 221a 348 ± 226a 349 ± 169a
24 h 164 ± 182 385 ± 216a 362 ± 131a 329 ± 148a
Delta of urine
NGAL (ng/ml)
0-3 h 10 ± 156 97 ± 92a 124 ± 106a 84 ± 138a
0-6 h 33 ± 131 187 ± 103a 227 ± 101a 217 ± 159a
0-12 h 20 ± 227 192 ± 108a 198 ± 108a 248 ± 152a
0-18 h 62 ± 186 112 ± 208a 132 ± 112a 162 ± 183a,
0-24 h 63 ± 174 168 ± 212a 145 ± 110a 212 ± 192a,
eGFR indicates estimated glomerular filtration rate.
aP <0.05 compared with No-CI-AKI.
bP <0.05 compared with CI-AKI (S1).
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levels at 0–6 h and 0–12 h were significantly higher in
the CI-AKI stage II than the CI-AKI stage I (P < 0.05)
(Table 2A) respectively.
The uNGAL was significantly and inversely correlated
with eGFR (R = 0.25, P < 0.005; Figure 2), and hemoglobin
(R = 0.44, P < 0.01). However, uNGAL did not correlate
with other parameters, such as SCr, age, gender, blood pres-
sure, height, body weight and body mass index (P > 0.05).
The performance characteristics of uNGAL and delta
of uNGAL for diagnosis CI-AKI are shown in Table 3.
The ROC curves AUCs ranged from 0.78 to 0.86
(uNGAL), and 0.66 to 0.83 (delta of uNGAL) (Table 3A).
The highest AUCs for uNGAL and delta of uNGAL for
diagnosis CI-AKI were 0.85 (95% CI = 0.76–0.91; P < 0.01)
at 6 h (Figure 3A) and 0.83 (95% CI = 0.75–0.92; P < 0.01)
at 0–6 h (Figure 3B), respectively. The cut-off value of
uNGAL for optimal combination of sensitivity (94%) and
specificity (78%) was 117 ng/mL, while the cut-off value of
delta of uNGAL for optimal combination of sensitivity
(88%) and specificity (80%) was 45 ng/mL, respectively.
The cut-off value of uNGAL and delta of uNGAL for
diagnosis CI-AKI in CKD stage III were similar to all
patients (Table 3B). However, the cut-off value of uNGAL
and delta of uNGAL for diagnosis CI-AKI in CKD stage
IV were higher than CKD stage III and all patients
(Table 3B).
The performance characteristics of uNGAL and delta
of uNGAL for diagnosis CI-AKI stage I are shown inFigure 2 Univariate baseline statistical correlations (Pearson coefficieTable 4. The best AUCs for uNGAL and delta of uNGAL
for diagnosis CI-AKI stage I were 0.83 (95% CI = 0.74–0.92;
P <0.01) at 6 h and 0.82 (95% CI = 0.72–0.92; P < 0.01) at
0–6 h post coronary procedure (Table 4A). The sensitiv-
ities were 92% and 85% while the specificities were 76%
and 80% when the cut-off values of uNGAL and delta of
uNGAL were 117 and 54 ng/mL (Table 4A), respectively.
The cut-off value of uNGAL and delta of uNGAL for
diagnosis CI-AKI stage I in CKD stage III were similar to
all patients (Table 4B). However, the cut-off value of
uNGAL and delta of uNGAL for diagnosis CI-AKI stage I
in CKD stage IV were higher than CKD stage III and all
patients (Table 4B).
The performance characteristics of uNGAL and delta of
uNGAL for diagnosis CI-AKI stage II are shown in Table 5.
The best AUCs for uNGAL and delta of uNGAL for
diagnosis CI-AKI stage II were 0.9 (95% CI = 0.84–0.97;
P < 0.01) at 6 h and 0.93 (95% CI = 0.86–0.99; P < 0.01) at
0–6 h post coronary procedure (Table 5A). The cut-off
value of uNGAL for optimal combination of sensitivity
(100%) and specificity (87%) was 264 ng/mL, while the
cut-off value of delta of uNGAL for optimal combination
of sensitivity (100%) and specificity (87%) was 121 ng/mL
(Table 5A). The cut-off value of uNGAL and delta of
uNGAL for diagnosis CI-AKI stage II in CKD stage III
were similar to all patients (Table 5B). In addition, the
cut-off value of uNGAL and delta of uNGAL for diagnosis
CI-AKI stage II in CKD stage IV were higher than CKD
stage III and all patients (Table 5B).nt) of urine NGAL and baseline eGFR.
Table 3 Diagnostic characteristics of urine NGAL for CI-AKI, stratified by baseline and postoperative time in all patient
(3A), CKD stage III and CKD stage IV (3B)
3A
All patients (N = 130)
ROC (95% CI) Cut point (ng/ml) Sensitivity (%) Specificity (%)
uNGAL
baseline 0.78 (0.68 to 0.87) 75 77 74
3 h 0.80 (0.69 to 0.89) 104 77 76
6 h 0.85 (0.76 to 0.91) 117 94 78
12 h 0.82 (0.74 to 0.90) 142 88 76
18 h 0.84 (0.76 to 0.91) 161 82 76
24 h 0.86 (0.79 to 0.93) 184 82 81
Delta of uNGAL
0-3 h 0.66 (0.49 to 0.79) 22 85 78
0-6 h 0.83 (0.75 to 0.92) 45 88 80
0-12 h 0.80 (0.72 to 0.89) 71 88 79
0-18 h 0.78 (0.67 to 0.90) 77 82 73
0-24 h 0.79 (0.67 to 0.91) 71 77 74
3B
CKD stage III (N = 100) CKD stage IV (N = 30)













baseline 0.72 (0.61 to 0.83) 61 70 71 0.87 (0.73 to 1.0) 84 86 73
3 h 0.79 (0.65 to 0.93) 108 80 78 0.88 (0.75 to 1.0) 155 86 82
6 h 0.82 (0.72 to 0.92) 117 92 80 0.89 (0.80 to 1.0) 207 86 86
12 h 0.77 (0.67 to 0.88) 142 84 75 0.86 (0.72 to 0.99) 281 86 83
18 h 0.81 (0.72 to 0.89) 161 70 76 0.83 (0.68 to 0.97) 285 83 78
24 h 0.82 (0.74 to 0.92) 184 78 81 0.88 (0.75 to 1.0) 235 86 83
Delta of uNGAL
0-3 h 0.80 (0.64 to 0.96) 24 90 78 0.75 (0.49 to 1.0) 22 86 78
0-6 h 0.82 (0.69 to 0.95) 42 91 79 0.89 (0.77 to 1.0) 54 100 87
0-12 h 0.76 (0.64 to 0.88) 65 82 77 0.88 (0.75 to 1.0) 71 100 83
0-18 h 0.80 (0.71 to 0.89) 77 88 73 0.73 (0.47 to 1.0) 102 86 83
0-24 h 0.81 (0.70 to 0.91) 61 80 74 0.73 (0.47 to 0.99) 91 71 78
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This prospective study in CKD patients undergoing
coronary procedure has demonstrated that uNGAL at
6 h and delta of uNGAL 0–6 h post coronary procedure
were good biomarkers for early diagnosis CI-AKI and
had some value in grading its severity. Baseline uNGAL
inversely correlated with the eGFR but did not correlate
with the SCr, suggesting it is a better marker for renal
impairment than SCr. Thus, monitoring the baseline
uNGAL could be a simple surrogate marker correspond
to baseline renal function and following the uNGAL
especially at 6 h after coronary procedure predict the
development and severity of CI-AKI.The findings from the present study confirm that
uNGAL is an important biomarker reflects the residual
renal function in CKD patients similar to previous
clinical studies have been reported [33-35] which explain
the role of this protein in glomerular filtration and tubu-
lar adaptation during chronic kidney injury. NGAL was
originally expressed in activated human neutrophils, but
it is also expressed at low levels in different human
tissues, including the distal nephron of kidney [36].
NGAL is synthesized systemically during kidney injury
followed by glomerular filtration and impaired proximal
tubular reabsorption. Moreover, NGAL was produced
locally by injured distal nephron epithelium resulting in
Figure 3 Receiver operating characteristics (ROC) curves of urine NGAL at baseline, 3 h, and 6 h (3A) and delta of urine NGAL 0–3 h,
0–6 h, and 0–12 h (3B) considering incidence of CI-AKI as status variable.
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NGAL by the chronic stressed kidney is responsible for
the increase uNGAL levels that reflect the residual renal
function superior than SCr in CKD patients.
Serial uNGAL in our CKD patients rose early since
3 h and peaked at 18 h after coronary procedures. These
kinetics are quite different to the patients with normal
renal function [26,28] whose uNGAL concentrations
peak earlier at 6–8 h and begin to return at 8–12 h after
coronary procedures. This difference is probably due to
the delayed excretion of contrast media in CKD patients
with continuing contrast induced kidney injury. Not
surprisingly, our baseline and serial uNGAL concentra-
tions are higher than those reported from studies with
patients with normal renal function.
Previous studies have shown the value of uNGAL for
early diagnosis CI-AKI in patients with normal renal func-
tion undergoing coronary procedures [25-27]. Hirsch
et al. [25] determined the diagnosis of CI-AKI in 91 con-
genital heart disease pediatric patients with normal renal
function undergoing cardiac catheterization and angiog-
raphy. The mean baseline uNGAL level was 17.7 ng/mL
and the levels of uNGAL increased 7 fold in CI-AKI
patients at 2 h after procedures. Using a cut-off value of
uNGAL 100 ng/ml at 6 h, the sensitivity, specificity, and
AUC for predicting CI-AKI were excellent; 90%, 99%, and
0.97, respectively. Ling et al. [27] reported the diagnosis of
CI-AKI in adult patients with normal renal function
undergoing coronary angiography. Baseline uNGALlevel was 5.76 ng/mL and increased two fold in CI-
AKI patients at 24 h after procedures. Using a cut-off
value of 9.85 ng/mL, the sensitivity, specificity, and
AUC for prediction of CI-AKI were good for the 24 h
uNGAL (77%, 70%, and 0.73, respectively). Bachorzewska-
Gajewska et al. [26] determined the diagnosis of CI-AKI
in 100 patients with normal SCr undergoing coronary
interventions. The mean baseline uNGAL level was
9.9 ng/mL and this increased significantly two fold at 4 h
after interventions. Furthermore, the uNGAL levels were
significantly higher in the patients with CI-AKI at 4 h after
procedures when compared with patients without CI-AKI.
Broadly, these studies had the baseline and follow-up
uNGAL levels after coronary procedures lower than the
present study because the population in the present study
was CKD patients who had renal dysfunction which delay
the kinetic change of uNGAL. Thus, the cut-off points of
uNGAL for detecting CI-AKI in CKD patients were
higher than patients with normal renal function.
In the present study, uNGAL and delta of uNGAL
were excellent biomarkers for detecting the development
CI-AKI in CKD patients undergoing elective coronary
procedures. The best time was 6 h for uNGAL and
between 0 to 6 h for delta of uNGAL. Therefore, at least
2 time points post baseline are needed for measuring
uNGAL and calculating delta of uNGAL to detect the
development of CI-AKI. More intense sampling may
have shown an earlier time to detect CI-AKI. At these
times, the uNGAL and delta of uNGAL levels were
Table 4 Diagnostic characteristics of urine NGAL for CI-AKI stage I, stratified by baseline and postoperative time in all
patient (4A), CKD stage III and CKD stage IV (4B)
4A
All Patients (N = 130)
ROC (95% CI) Cut point (ng/ml) Sensitivity (%) Specificity (%)
uNGAL
baseline 0.77 (0.65 to 0.89) 74 77 72
3 h 0.82 (0.71 to 0.94) 108 85 76
6 h 0.83 (0.74 to 0.92) 117 92 76
12 h 0.82(0.72 to 0.91) 142 85 73
18 h 0.84 (0.76 to 0.92) 161 83 74
24 h 0.85 (0.77 to 0.93) 181 85 79
Delta of uNGAL
0-3 h 0.75 (0.58 to 0.91) 22 85 78
0-6 h 0.82 (0.72 to 0.92) 54 85 80
0-12 h 0.79 (0.68 to 0.88) 71 85 76
0-18 h 0.77 (0.63 to 0.91) 77 92 72
0-24 h 0.77 (0.62 to 0.92) 71 77 73
4B
CKD stage III (N = 100) CKD stage IV (N = 30)













baseline 0.70 (0.58 - 0.81) 41 78 58 0.90 (0.78 - 1.0) 140 100 88
3 h 0.77 (0.62 - 0.92) 108 78 78 0.89 (0.77 - 1.0) 162 100 79
6 h 0.80 (0.70 - 0.91) 117 89 79 0.89 (0.75 - 1.0) 239 100 80
12 h 0.76 (0.69 - 0.87) 142 78 74 0.83 (0.66 1.0) 276 100 63
18 h 0.80 (0.70 - 0.89) 130 78 72 0.85 (0.68 - 1.0) 242 100 73
24 h 0.82 (0.72 - 0.92) 160 78 79 0.90 (0.78 - 1.0) 184 100 77
Delta of uNGAL
0-3 h 0.79 (0.62 - 0.96) 24 89 77 0.81 (0.64 - 0.97) 22 100 73
0-6 h 0.80 (0.66 - 0.94) 42 89 78 0.84 (0.70 - 0.98) 65 100 77
0-12 h 0.75 (0.63 - 0.89) 74 78 77 0.82 (0.66 - 0.97) 71 100 76
0-18 h 0.81 (0.71 - 0.90) 77 89 73 0.61 (0.19 - 1.0) 102 75 73
0-24 h 0.81 (0.70 - 0.90) 71 78 77 0.62 (0.19 - 1.0) 44 75 54
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patients but numbers are small and concern is advised
in generalizing these results. Caution should be exer-
cised when comparing across studies because studies
have used different patients population, diagnostic cri-
teria of CI-AKI definitions, storage conditions of urine
specimens, and techniques for measuring uNGAL and
others confounding factors.
Cut-off points of uNGAL at 6 h and delta of uNGAL
0–6 h predict the severity of CI-AKI in CKD patients
undergoing elective coronary procedures. Although the
numbers of CI-AKI patients in the present study were
small but there was a suggestion that uNGAL and deltaof uNGAL levels were higher on patients who developed
CI-AKI stage II when compared to those with CI-AKI
stage I for 2–3 times. This is an area where more data
are needed to validate the levels of uNGAL, the degree
of renal impairment and if this also predicts later
morbidity.
The present study has limitations. First, the present
study has only been conducted in a single center. These
results will need to be validated in a larger population by
perform a multi-center study. Second, NGAL measure-
ment by ELISA kit in the present study detect the high
molecular weight NGAL complex which may lack
sensitivity. Nickolas et al. [37] have demonstrated that
Table 5 Diagnostic characteristics of urine NGAL for CI-AKI stage II, stratified by baseline and postoperative time in all
patient (5A), CKD stage III and CKD stage IV (5B)
5A
All patients (N = 130)
ROC (95% CI) Cut point (ng/ml) Sensitivity (%) Specificity (%)
uNGAL
baseline 0.76 (0.65 to 0.88) 82 100 70
3 h 0.86 (0.76 to 0.97) 135 100 77
6 h 0.9 (0.84 to 0.97) 264 100 87
12 h 0.85 (0.74 to 0.96) 204 100 79
18 h 0.8 (0.72 to 0.88) 186 100 76
24 h 0.78 (0.7 to 0.86) 175 100 74
Delta of uNGAL
0-3 h 0.87 (0.77 to 0.97) 53 100 81
0-6 h 0.93 (0.86 to 0.99) 121 100 87
0-12 h 0.82 (0.67 to 0.98) 65 100 71
0-18 h 0.77 (0.63 to 0.91) 83 100 67
0-24 h 0.76 (0.64 to 0.88) 61 100 68
5B
CKD stage III (N = 100) CKD stage IV (N = 30)











baseline 0.88 (0.0 to 1.0) 143 100 88 0.60 (0.42 to 0.79) 82 100 59
3 h 0.92 (0.0 to 1.0) 220 100 92 0.74 (0.48 to 1.0) 135 100 63
6 h 0.93 (0.0 to 1.0) 264 100 93 0.80 (0.56 to 1.0) 281 100 71
12 h 0.83 (0.0 to 1.0) 208 100 83 0.77 (0.51 to 1.0) 204 100 65
18 h 0.83 (0.0 to 1.0) 226 100 83 0.67 (0.48 to 0.85) 186 100 63
24 h 0.81 (0.0 to 1.0) 204 100 81 0.70 (0.52 to 0.87) 175 100 68
Delta of uNGAL
0-3 h 0.84 (0.0 to 1.0) 77 100 84 0.88 (0.72 to 1.0) 53 100 82
0-6 h 0.90 (0.0 to 1.0) 121 100 90 0.91 (0.77 to 1.0) 197 100 86
0-12 h 0.72 (0.0 to 1.0) 65 100 72 0.88 (0.68 to 1.0) 120 100 78
0-18 h 0.69 (0.0 to 1.0) 83 100 69 0.78 (0.61 to 0.95) 102 100 71
0-24 h 0.70 (0.0 to 1.0) 61 100 70 0.79 (0.60 to 0.98) 91 100 71
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lated with GFR and renal cell types. Thus, a more specific
assay of the NGAL monomer could be developed for early
detect CI-AKI. Finally, several potential urine and plasma
proteins were demonstrated to early diagnosis CI-AKI. It
could take the advantage if the author will combine two
or more biomarkers at different time points from 0–12 h
after coronary procedure which can improve the diagnos-
tic accuracy.
Conclusions
Monitoring of uNGAL levels at baseline and 6 h post
elective coronary procedures in CKD patients had highsensitive and specificity for early diagnosis CI-AKI and
showed some discriminatory value for CI-AKI severity.
It should be used in favour of SCr for identifying early
patients who develop CI-AKI.Abbreviations
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